PRMA Consulting - Fishawack Health
Pharma Focus Asia
Cytiva
EVA Air Cargo - 2022

C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Latest Issue
Get instant access to latest e-book

LATEST NEWSRead more...

30

Jun 2022

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

Pfizer Inc and BioNTech SE announced a new vaccine supply agreement with the US government to support the continued fight against COVID Under the agreement the US government will receive million doses g g and g This may include adult Omicronadapted COVID vaccines subject to authorization from th...

30

Jun 2022

Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets

Generian Pharmaceuticals Inc and Mitobridge Inc announced today that they have entered into a collaboration and exclusive license agreement to discover and develop novel small molecules for undruggable therapeutic targets by using a proprietary drug discovery platform for diseases that have limited...

29

Jun 2022

Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic

Akoya Biosciences Inc The Spatial Biology Company and Acrivon Therapeutics Inc a clinicalstage oncology therapeutics company with proprietary technologies driving a new era of precisionbased medicine today announced an agreement to codevelop validate and commercialize Acrivons OncoSignature test a f...

29

Jun 2022

Fate Therapeutics Announces Expansion of Solid Tumor Collaboration with ONO Pharmaceutical for Off-the-Shelf, iPSC-derived CAR NK and CAR T-Cell Cancer Immunotherapies

Fate Therapeutics Inc a clinicalstage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer today announced that it has expanded its offtheshelf iPSCderived cellbased cancer immunotherapy collaboration with ONO Pharmaceutical Co Ltd ON...

28

Jun 2022

Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

Hillstream BioPharma Inc a biotechnology company developing novel therapeutic candidates targeting ferroptosis an emerging new anticancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers today announced a collaboration with Sapien Biosciences to evaluate the...

28

Jun 2022

Arzeda Announces Collaboration with W. L. Gore & Associates to Drive Innovation in Materials Research with Designer Proteins

Arzeda the industryleading Protein Design Company announced today that it is collaborating with W L Gore Associates a global leader in advanced materials science on research leveraging Arzedas technology platform that economically and efficiently creates new and enhances existing proteins

press releasesRead more...

29

Jun 2022

EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review

Regeneron Pharmaceuticals Inc announced the US Food and Drug Administration FDA has accepted for review the EYLEA aflibercept Injection supplemental Biologics License Application sBLA for an every week mg dosing regimen after initial monthly doses in patients with diabetic retinopathy DR The target...

29

Jun 2022

Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication

Ocuphire Pharma Inc a clinicalstage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders today announced that the United States Patent and Trademark Office USPTO has issued a new patent extending expiry and...

28

Jun 2022

WuXi STA Opens A High-Potency API Plant

WuXi STA a WuXi AppTec company has opened another highpotency API HPAPI plant at its Changzhou site Jiangsu China The new plant will meet the growing demand for highpotency API process RD and manufacturing services and consists of reactors from L to L prepHPLC systems a m tray lyophilizer as well...

28

Jun 2022

Vetter’s Newest Clinical Manufacturing Site Successfully Completed its First Customer Fills

With the realization of the first successful customer fills Vetter a leading global Contract Development and Manufacturing Organization CDMO has reached another milestone at its new clinical manufacturing facility in Rankweil Austria Further batches are already planned and more customer projects are...

28

Jun 2022

ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology

ProPhase Labs Inc a diversified diagnostics and genomics company today announced the formation of whollyowned subsidiary ProPhase BioPharma Inc PBIO for the licensing and development of novel drugs compounds and biotechnology PBIO will focus on advanced technology in the biochemical industry and cre...

28

Jun 2022

Beyond Air’s LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

Beyond Air Inc a clinicalstage medical device and biopharmaceutical company focused on developing inhaled nitric oxide NO for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension and through its affiliate Beyond Cancer ultrahigh concentra...

EventsRead more...

28 - 30

Jun 2022

4th Annual Longevity Therapeutics Summit 2022

Hanson Wade
Marines' Memorial Club & Hotel

29 - 30

Jun 2022

Onco Cell Therapy Summit

Boston

08 - 09

Jul 2022

i- Pharma Conference 2022

London

11 - 13

Jul 2022

Neurological Disorders Europe

Hanson Wade
Pullman Paris La Défense

12 - 14

Jul 2022

In Vivo Engineering of Therapeutic Cells Summit

Hanson Wade
Hyatt Regency Boston

12 - 14

Jul 2022

Combination Targeted Oncology

Monica Mojumder Chan
Hilton Boston Back Bay

14 - 15

Jul 2022

i-Pharma 2022

London

18 - 20

Jul 2022

Generation Gene Therapy Vectors

Hanson Wade
The Westin Boston Seaport District

Testing The World Celebrating 70 Years of Nalgene
Development and Validation of a Platform Assay Method Using Variable Pathlength Technology for Oligonucleotide Drug Products
Catalent - Clinical Supply Solutions
MasterControl - Choose the Modern Manufacturing Software That’s Right for You
Biologics Manufacturing Korea 2022
Medical Fair Asia 2022
Medical Manufacturing Asia 2022
THERMOFISHER SEA APAC EDC
APAC CT Design
APAC Pharma Virtual
Upm Raflatac
TFS
TFS
TFS
TFS
SUB
SUB
SUB

TOP ARTICLES

KNOWLEDGE BANK

  • Interviews

    Innovation Management At Bachem

    Innovation Management at Bachem

    Chief Technology Officer, Bachem Holding AG

    Gnther Loidl joined Bachem in He held several functions in Research and Development RD and Active Pharmaceutical Ingredient Manufacturing and became Vice President RD in Since he is CTO of the Bachem Group and a member of the Corporate Executive Committee He studied chemistry in Regensburg Germany and Leeds UK and obtained his doctorate under the supervision of Luis Moroder at the Max Planck In...

  • Case Studies

    Diagnostics - Stable Aqueous Horseradish Peroxidase

    Challenge The main use of Horseradish peroxidise HRP is in diagnostic applications to produce a detectable signal indicating presence of a molecular target Typically HRP is used in conjugates with antibodies the antibody to recognise the molecular target an

  • Techno Trends

    Asterias’ Novel Immunotherapy Treatment AST-VAC2 Moves into Clinical Trials

    The charity Cancer Research UK and its commercial arm Cancer Research Technology CRT have entered into an agreement with US biotech firm Asterias Biotherapeutics a subsidiary of BioTime Inc to conduct clinical trials of Asterias novel immunotherapy treatment ASTVAC in subjects with nonsmall cell lung cancer ASTVAC is a nonpatient specific allogeneic canc

Advisory Board

Stella Stergiopoulos

Stella

 .
Sanjoy Ray

Sanjoy Ray

 .
Rustom Mody

Rustom

 .
Phil Kaminsky

Phil

 .
Neil J Campbell

Neil J
Laurence Flint

Laurence

 .
Kenneth I Kaitin

Kenneth I

 .
Georg C Terstappen

Georg C

 .
Frank A Jaeger

Frank A

 .
Douglas Meyer

Douglas

 .
Christopher-Paul Milne

Christopher-
Alan S Louie

Alan S Louie

 .

EDITORIAL SECTION

  • EXPERT Talk

    PHARMA LOGISTICS TRENDS

    Pharma logistics is undergoing profound change throughout Asia as the ageing population drives a growing need for new pharma solutions together with s...